Cancer Immunology Research

1.7k papers and 74.4k indexed citations i.

About

The 1.7k papers published in Cancer Immunology Research in the last decades have received a total of 74.4k indexed citations. Papers published in Cancer Immunology Research usually cover Immunology (1.2k papers), Oncology (1.1k papers) and Molecular Biology (434 papers) specifically the topics of Cancer Immunotherapy and Biomarkers (667 papers), Immunotherapy and Immune Responses (590 papers) and Immune Cell Function and Interaction (527 papers). The most active scholars publishing in Cancer Immunology Research are F. Stephen Hodi, Elizabeth M. Jaffee, Jedd D. Wolchok, Glenn Dranoff and Charles G. Drake.

In The Last Decade

Fields of papers published in Cancer Immunology Research

Since Specialization
EngineeringComputer SciencePhysics and AstronomyMathematicsEarth and Planetary SciencesEnergyEnvironmental ScienceMaterials ScienceChemical EngineeringChemistryAgricultural and Biological SciencesVeterinaryDecision SciencesArts and HumanitiesBusiness, Management and AccountingSocial SciencesPsychologyEconomics, Econometrics and FinanceHealth ProfessionsDentistryMedicineBiochemistry, Genetics and Molecular BiologyNeuroscienceNursingImmunology and MicrobiologyPharmacology, Toxicology and Pharmaceutics

This network shows the specialization of papers published in Cancer Immunology Research. Nodes represent fields, and links connect fields that are likely to share authors.

Countries where authors publish in Cancer Immunology Research

Since Specialization
Total citations of papers

This map shows the geographic distribution of research published in Cancer Immunology Research. It shows the number of citations received by papers published by authors working in each country. You can also color the map by specialization and compare the number of papers published in Cancer Immunology Research with the expected number of papers based on a country's size and research output (numbers larger than one mean the country's share of papers is larger than expected).

Rankless by CCL
2025